

ESP Advanced Training Centre in the area of Liver Pathology

Heidelberg, Germany

Specialist fields

Liver pathology

Special techniques (open also to technicians/medical scientists)

Hepatobiliary pathology

Centre specification

Name of the centre and address

Institute of Pathology
University Hospital Heidelberg
Im Neuenheimer Feld 224
69120 Heidelberg

Chair of the centre

Prof. Dr. P. Schirmacher

Head of the training programme

Prof. Dr. P. Schirmacher

Details about specific training areas (particular method, field of subspeciality)

Hepatobiliary Pathology

Conditions

The center will offer one trainee position in Liver Pathology at a time. The duration should be not more than 3 months, shorter periods are possible for applicants with advanced knowledge. We accept applicants all year round except for middle December till middle of January and during August/beginning of September. We will not charge the training and support will be given in finding an accommodation for a reasonable local price. If required we will support the applicant to obtain the necessary visa and other documents and send a letter of invitation as well as we will agree on duration and time of the stay beforehand. After completion of the training period the trainee will receive a detailed certificate describing the work.

Contact address for requests

Dr. Mandy Skunde
Institute of Pathology
Im Neuenheimer Feld 224, room 1.007
69120 Heidelberg
Tel: +49/ 6221 56 39186
Email: mandy.skunde@med.uni-heidelberg.de

Attachments:

1. Training measures
2. Publications of the last 5 years

Attachment 1:

Liver Pathology training measures:

- Participation in processing/reporting of daily routine cases (Macro-/Microscopy)
- Microscopy of case collection of liver cases under guidance of liver pathology experts (n>200)
- Participation in morphology based liver research project
- Participation in internal training measures (3 h weekly)
 - Residents training meeting (1h weekly)
 - Research in progress meeting (1h weekly)
 - Journal Club (1 h weekly)
- Participation in regular interdisciplinary meetings (7 h weekly)
 - Liver tumor board of Liver Cancer Center Heidelberg (LCCH) (weekly 2 h)
 - Surgical clinic-pathological conference (centered on hepato-pancreatico-biliary cases; weekly 1h)
 - Molecular tumor board with NCT (1 h weekly)
 - Business meetings of the LCCH (0,5 h weekly)

Trainers (Board certified Pathologists with specific Liver Pathology expertise):

Prof. Dr. P. Schirmacher

Prof. Dr. T. Longerich

Prof. Dr. D. Tschaharganeh

Dr. C. Flechtenmacher

Attachment 2:

Publications of the last 5 years:

Diagnostic Publications

Albrecht T, Rossberg A, Rose F, Breuhahn K, Baumann EM, Tóth M, Brinkmann F, Charbel A, Vogel MN, Köhler B, Mehrabi A, Büchler MW, Singer S, Solass W, Straub B, Schirmacher P, Roessler S, Goeppert B. Combined analysis of albumin in situ hybridisation and C reactive protein immunohistochemistry for the diagnosis of intrahepatic cholangiocarcinoma: towards a molecular classification paradigm. *J Clin Pathol.* 2025 Apr 17;78(5):307-316.

Puzalkova AV*, Hofmann K*, Pfeffer T, Klein IM, Mehrabi A, Merle U, **Stenzinger A, Penzel R, Flechtenmacher C, Schirmacher P.** High relevance of invasive fungal disease in chronic liver transplant failure: a comprehensive cross-sectional study. *Virchows Arch.* 2025 Aug;487(2):413-422.

Stenzinger A, Normanno N, Lamarca A, Rimassa L, Bibeau F, Tanriere P, Vogel A, Hollebecque A. From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology. *Expert Rev Mol Diagn.* 2025 Aug;25(8):495-508.

Straub BK, Müller L, Duret DS, **Tóth M**, Mittler J, **Schirmacher P**. Morphomolekulare Subtypisierung hepatozellulärer Adenome [Morphomolecular subtyping of hepatocellular adenoma]. Pathologie

Tóth M, Kirchner M, Longerich T, Stenzinger A, Schirmacher P. Integrated genotype-phenotype analysis of familial adenomatous polyposis-associated hepatocellular adenomas. Virchows Arch. 2024 Apr;484(4):587-595.

Longerich T, Stenzinger A, Schirmacher P. Molecular diagnostics of hepatobiliary and pancreatic neoplasias. Virchows Arch. 2024 Feb;484(2):263-272.

Stenzinger A, Vogel A, Lehmann U, Lamarca A, Hofman P, Terracciano L, Normanno N. Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing. Cancer Treat Rev. 2024 Jan;122:102649.

Schirmacher P, Trauner M, Lackner C, Weber A, Baba H.A., Evert M (2024) Kapitel 33: Leber und intrahepatische Gallenwege. in: Pathologie. Das Lehrbuch. Siebente Auflage. Höfler G, Kreipe H, Moch H (eds.), Elsevier, Deutschland, S. 637-678. ISBN: 978-3-437-42391-8.

Schirmacher P, Jochum W, Lackner C. (2024) Kapitel 34: Gallenblase und extrahepatische Gallenwege. in: Pathologie. Das Lehrbuch. Siebente Auflage. Höfler G, Kreipe H, Moch H (eds.), Elsevier, Deutschland, S. 679-684. ISBN: 978-3-437-42391-8.

Albrecht T, Rossberg A, Albrecht JD, Nicolay JP, Straub BK, Gerber TS, Albrecht M, **Brinkmann F, Charbel A, Schwab C, Schreck J, Brobeil A, Flechtenmacher C, von Winterfeld M**, Köhler BC, Springfield C, Mehrabi A, Singer S, Vogel MN, **Neumann O, Stenzinger A, Schirmacher P, Weis CA, Roessler S**, Kather JN, **Goeppert B**. Deep Learning-Enabled Diagnosis of Liver Adenocarcinoma. Gastroenterology. 2023 Nov;165(5):1262-1275.

Neumann O, Lehmann U, Bartels S, Pfarr N, **Albrecht T**, Ilm K, Christmann J, **Volckmar AL, Goldschmid H, Kirchner M, Allgäuer M**, Walker M, Kreipe H, Tannapfel A, Weichert W, **Schirmacher P, Kazdal D*, Stenzinger A***. First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma. J Pathol Clin Res. 2023 Mar;9(2):100-107.

Wiethoff H, Mohr I, Fichtner A, Merle U, **Schirmacher P**, Weiss KH, **Longerich T**. Metallothionein: a game changer in histopathological diagnosis of Wilson disease. Histopathology. 2023 Dec;83(6):936-948.

Longerich T, Schirmacher P. Molecular Pathology of Livers Tumors. In : Molecular Surgical Pathology 2023; Vol: 8, S. 201 – 230, ISBN : 978-3-031-35118-1 , doi: 10.1007/978-3-031-35118-1.

Research Publications

Ritz T*, Tanevski J*, Baues J, Loosen SH, Luedde T, Neumann U, Boor P, **Schirmacher P**, Saez-Rodriguez J, **Longerich T**. Proteomic subtyping highlights tumor heterogeneity of human HCC. Virchows Arch. 2025 Nov;487(5):959-969.

Tóth M, Wan S, Schmitt J, Birner P, Wei T, von Bubnoff F, de la Torre C, Thomann S, Pinna F, Schirmacher P, Weiler SME, Breuhahn K. The Cell Polarity Protein MPP5/PALS1 Controls the Subcellular Localization of the Oncogenes YAP and TAZ in Liver Cancer. *Int J Mol Sci.* 2025 Jan 14;26(2):660.

Grimsrud MM, Forster M, **Goeppert B**, Hemmrich-Stanisak G, Sax I, Grzyb K, Braadland PR, **Charbel A, Metzger C, Albrecht T**, Steiert TA, Schlesner M, Manns MP, Vogel A, Yaqub S, Karlsen TH, **Schirmacher P**, Boberg KM, Franke A, **Roessler S***, Folseraas T*. Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis. *Hepatol Commun.* 2024 Jul 5;8(7):e0461.

Liu K, Wehling L, Wan S, Weiler SME, Tóth M, Ibberson D, Marhenke S, Ali A, Lam M, Guo T, **Pinna F, Pedrini F, Damle-Vartak A**, Dropmann A, **Rose F**, Colucci S, Cheng W, **Bissinger M, Schmitt J, Birner P, Poth T**, Angel P, Dooley S, Muckenthaler MU, **Longerich T**, Vogel A, Heikenwälder M, **Schirmacher P, Breuhahn K**. Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication. *Cell Mol Life Sci.* 2024 Mar 4;81(1):115.

Sugiyanto RN, Metzger C, Inal A, Truckenmueller F, Gür K, Eiteneuer E, Huth T, Fraas A, Heinze I, Kirkpatrick J, Sticht C, **Albrecht T, Goeppert B, Poth T**, Pusch S, Mehrabi A, **Schirmacher P**, Ji J, Ori A, **Roessler S**. Proteomic profiling reveals CEACAM6 function in driving gallbladder cancer aggressiveness through integrin receptor, PRKCD and AKT/ERK signaling. *Cell Death Dis.* 2024 Oct 28;15(10):780.

Thomann S, Metzler T, Tóth M, Schirmacher P, Mogler C. Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas. *Hepatol Commun.* 2024 Jan 11;8(1):e0359.

Wesener MC*, Weiler SME*, Bissinger M, Klessinger TF, Rose F, Merker S, Luzarowski M, Ruppert T, Helm B, Klingmüller U, **Schirmacher P, Breuhahn K***. CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer. *Int J Mol Sci.* 2024 Aug 5;25(15):8549.

Huth T, Dreher EC, Lemke S, Fritzsche S, Sugiyanto RN, Castven D, Ibberson D, Sticht C, **Eiteneuer E**, Jauch A, Pusch S, **Albrecht T, Goeppert B**, Candia J, Wang XW, Ji J, Marquardt JU, Nahnsen S, **Schirmacher P, Roessler S**. Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer. *Sci Adv.* 2023 Dec 22;9(51):eadh1442.

Tang Y, Thiess L, Weiler SME, Tóth M, Rose F, Merker S, Ruppert T, **Schirmacher P, Breuhahn K**. α -catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration. *Cell Commun Signal.* 2023 Jun 28;21(1):162.